Gene · 3601
Papers2,328
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
581 to 600 of 2,328
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. | Nat Med | 2022 | 35484264 | PubTator, text mining | PubMed |
| Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. | Int Immunopharmacol | 2022 | 35483235 | PubTator, text mining | PubMed |
| Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19. | Front Immunol | 2022 | 35479098 | PubTator, text mining | PubMed |
| A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells. | Transl Oncol | 2022 | 35477065 | PubTator, text mining | PubMed |
| Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy. | Sci Adv | 2022 | 35476449 | PubTator, text mining | PubMed |
| Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy. | Mol Cancer | 2022 | 35459256 | PubTator, text mining | PubMed |
| Development of CAR T Cell Therapy in Children-A Comprehensive Overview. | J Clin Med | 2022 | 35456250 | PubTator, text mining | PubMed |
| Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents. | Biomedicines | 2022 | 35453618 | PubTator, text mining | PubMed |
| Environmental induced transgenerational inheritance impacts systems epigenetics in disease etiology. | Sci Rep | 2022 | 35440735 | PubTator, text mining | PubMed |
| Networks of CD8+ T Cell Response Activation in Melanoma and Vitiligo. | Front Immunol | 2022 | 35432377 | PubTator, text mining | PubMed |
| Emerging Strategies in TCR-Engineered T Cells. | Front Immunol | 2022 | 35432319 | PubTator, text mining | PubMed |
| Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer. | Stem Cell Res Ther | 2022 | 35414042 | PubTator, text mining | PubMed |
| Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. | Nat Commun | 2022 | 35411050 | PubTator, text mining | PubMed |
| Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. | Mol Cancer | 2022 | 35410257 | PubTator, text mining | PubMed |
| The Human Monocyte-A Circulating Sensor of Infection and a Potent and Rapid Inducer of Inflammation. | Int J Mol Sci | 2022 | 35409250 | PubTator, text mining | PubMed |
| Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies. | Cells | 2022 | 35406692 | PubTator, text mining | PubMed |
| Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy. | Front Immunol | 2022 | 35401529 | PubTator, text mining | PubMed |
| A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells. | Front Oncol | 2022 | 35392221 | PubTator, text mining | PubMed |
| Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. | Signal Transduct Target Ther | 2022 | 35387984 | PubTator, text mining | PubMed |
| Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control. | J Clin Invest | 2022 | 35380989 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3601/papers?page=30